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Rapid assessment of Hib disease burden in
Vietnam
Batmunkh Nyambat1*, Duc Anh Dang2, Hien Anh Nguyen2, Trinh Quynh Mai2, Manju Rani3, Mary PE Slack4 and
Paul E Kilgore1

Abstract
Background: Several countries have applied the Haemophilus influenzae type b (Hib) rapid assessment tool (RAT)
to estimate the burden of Hib disease where resources for hospital- or population-based surveillance are limited. In
Vietnam, we used the Hib RAT to estimate the burden of Hib pneumonia and meningitis prior to Hib vaccine
introduction.
Methods: Laboratory, hospitalization and mortality data were collected for the period January 2004 through
December 2005 from five representative hospitals. Based on the WHO Hib RAT protocol, standardized MS Excel
spreadsheets were completed to generate meningitis and pneumonia case and death figures.
Results: We found 35 to 77 Hib meningitis deaths and 441 to 957 Hib pneumonia deaths among children < 5
years of age annually in Vietnam. Overall, the incidence of Hib meningitis was estimated at 18/100,000 (95%
confidence interval, CI, 15.1-21.6). The estimated Hib meningitis incidence in children < 5 years age was higher in
Ho Chi Minh City (22.5/100,000 [95% CI, 18.4-27.5]) compared to Hanoi (9.8/100,000 [95% CI, 6.5-14.8]). The Hib RAT
suggests that there are a total of 883 to 1,915 cases of Hib meningitis and 4,414 to 9,574 cases of Hib pneumonia
per year in Vietnam.
Conclusions: In Hanoi, the estimated incidence of Hib meningitis for children < 5 years of age was similar to that
described in previous population-based studies of Hib meningitis conducted from 1999 through 2002. Results from
the Hib RAT suggest that there is a substantial, yet unmeasured, disease burden associated with Hib pneumonia in
Vietnamese children.
Keywords: Hib vaccine, RAT, disease burden

Background
Prior to the introduction of universal childhood immunization with Haemophilus influenzae type b (Hib) vaccine, Hib was the most common cause of lifethreatening bacterial infection (most often resulting in
meningitis, bacterial pneumonia, and sepsis) in young
children in industrialized countries [1]. Haemophilus
influenzae, including Hib, is a well-known cause of
childhood and adult disease with manifestations that
include pneumonia, meningitis, epiglottitis, empyema,
septicemia, septic arthritis, osteomyelitis, pericarditis,
and cellulitis [2,3]. Globally, Hib is responsible for an
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estimated 3 million cases of serious disease and 386,000
childhood deaths every year [4]. Since the introduction
of Hib conjugate vaccines in many countries, the decline
in Hib disease burden has been documented in several
countries where the Hib conjugate vaccine is in routine
use [5-7]. To date, the Hib conjugate vaccine has been
considered safe and highly effective [8].
Over the past decade, relatively few studies have documented the burden of Hib disease among Asian children
[9,10]. This limited evidence has hindered the introduction of Hib vaccines in some countries. Thus, the assessment of Hib disease burden in children is an important
pre-requisite for informing policymakers of the value of
routine Hib immunization [11]. However, measuring
Hib disease burden is not straightforward, particularly in
countries with limited microbiological laboratory
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diagnostic capacity and antibiotic overuse. Although Hib
meningitis exacts high costs from the health-care system
and society due to its severity and associated long-term
sequelae, it is believed that the majority of Hib disease
in developing countries is manifested as pneumonia
[12,13].
For many countries, local disease burden assessments
may be obtained using Ministry of Health (MOH) surveillance data and a review of the local scientific literature. However, this strategy may not be possible where
surveillance data is limited. In 2006, the Ministry of
Health in Vietnam initiated consideration of Hib conjugate vaccine introduction into the national Expanded
Programme on Immunization (EPI). To support decisions regarding the use of Hib vaccines in Vietnam, we
conducted a rapid assessment of the Hib disease burden
using a standardized rapid assessment tool (RAT) developed by WHO [14]. The objective of this study was to
estimate the incidence of Hib meningitis and Hib pneumonia among children < 5 years of age in Vietnam. The
results of this assessment will be compiled with data
from other clinical, epidemiologic and laboratory studies
of Hib disease to provide a more comprehensive picture
of the Hib disease burden among children in Vietnam.

Methods
Vietnam is located in Southeast Asia and has a total
population estimated at 86 million persons [15]. Vietnam’s public health sector is highly regarded globally,
and it is renowned for an efficient public health system
capable of delivering routine EPI vaccines at sustained
high coverage rates. Hanoi and Ho Chi Minh City (Vietnam’s major cities) have the largest urban populations
in the country, and contain several major children’s hospitals, which include Pediatric Hospital #1 and Pediatric
Hospital #2 in Ho Chi Minh City, and National Pediatric Hospital, Bach Mai Hospital, and St. Paul Hospital
in Hanoi (Table 1).
This study applied the Hib RAT, which was developed
by the WHO, to estimate the Hib disease burden in
Table 1 Study hospital and population characteristics,
Vietnam
Hospital
name

Total Beds (Pediatric
beds)

City

Bach Mai

350 (30)

Hanoi 0-59 months:
217639

St. Paul

500 (138)

National
Pediatric

580

Hospital #1

1000

Hospital #2

1000

1

Population, # < 5
yrs1

HCMC 0-59 months:
406451

Population data from Vietnam national census office.

Vietnam [16]. A retrospective analysis was conducted
using existing data, specifically the numbers of meningitis and pneumonia cases and deaths in children < 5
years of age that may be attributable to Hib infection.
The Hib RAT calculations utilize two methods for
determining meningitis and pneumonia cases and deaths
(the meningitis incidence rate method and the underfive mortality rate method). The meningitis incidence
rate method uses local estimates of Hib meningitis incidence based on analysis of retrospective data from hospitals or from other local Hib studies in order to
estimate the national burden of total Hib disease. The
under-five mortality rate method uses the proportion of
childhood deaths from acute lower respiratory infection
(ALRI) attributable to Hib (13%) to the total number of
under-five deaths due to ALRI, minus the neonatal
deaths unlikely to be due to Hib infection [12]. Backward calculations are then done to estimate the total
number of Hib pneumonia and meningitis cases, which
are based on estimated case-fatality rates for Hib pneumonia and meningitis.
For data collection, the study team visited five major
children’s hospitals in Hanoi and Ho Chi Minh City.
These hospitals were identified for the study by Vietnam’s National Institute of Hygiene and Epidemiology
(NIHE). These hospitals were selected because each had
well-established clinical and microbiological facilities
that were capable of assessing children with severe disease, including pneumonia, meningitis, and sepsis, as
well as laboratory capability for the identification of
Haemophilus influenzae [16]. In each of the hospitals,
discharge records were inspected over a two-year period
(January 2004 through December 2005) to identify any
child less than five years of age who had a diagnosis of
meningitis based on the International Classification of
Diseases, 10th Revision (ICD-10) diagnostic codes. After
identification of children hospitalized with meningitis, a
complete medical chart review was conducted to identify children with purulent meningitis characterized by
abnormal cerebrospinal fluid (CSF). In addition to medical chart review, all microbiological records for the period from January 2004 through December 2005 were
reviewed to identify invasive Haemophilus influenzae
isolates from CSF or blood culture laboratory specimens. The study team also collected data on mortality
rates among infants and children < 5 years of age from
the Vietnam Ministry of Health in order to estimate the
number of deaths associated with Hib [17].
Three Microsoft Excel worksheets from the standardized WHO Hib RAT protocol were used to enter information on the number of patients with purulent
meningitis, number of patients with clinical meningitis
who had a lumbar puncture performed, number of
patients with Hib isolated in CSF, population of children
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< 5 years of age, previous estimates of Hib meningitis
incidence, ratio of Hib pneumonia to Hib meningitis (5
to 1), and Hib meningitis and Hib pneumonia case fatality rates [14,16]. Using these inputs, the annual Hib
meningitis incidence rate was calculated. Ninety-five
percent confidence intervals (CIs) for incidence rates
were calculated by the Wilson score method [18]. Two
additional standardized worksheets were completed to
estimate the total number of cases and deaths associated
with both Hib meningitis and pneumonia. This study
was approved by the International Vaccine Institute’s
Institutional Review Board (IRB) and the National Institute of Hygiene and Epidemiology’s (NIHE) scientific
and ethical review committee. Human experimentation
guidelines of the authors’ institution(s) were followed in
the conduct of clinical research.

Results
Suspected, purulent, and confirmed bacterial and Hib
meningitis

Based on available data from the three children’s hospitals
in Hanoi during the two-year study period from January
2004 through December 2005, we found 145 cases of suspected meningitis, 85 cases of purulent meningitis, including 17 cases with a bacterial pathogen identified, and 10
cases in which Hib was detected (Table 2). There were no
in-hospital deaths due to Hib meningitis identified in the
Hanoi hospitals. In Ho Chi Minh City, a total of 1,115
cases of suspected meningitis were found over the two-year
study period. In addition, hospitalization and laboratory
records showed that 404 children were hospitalized with
purulent meningitis of which 34 children had a bacterial
pathogen. Of these, Hib was identified from 15 (44.1%)
patients. One death due to Hib meningitis was identified
from the two children’s hospitals in Ho Chi Minh City.
Total estimated cases of Hib meningitis and Hib
pneumonia

Using the standardized worksheet calculations for the
“incidence rate” method, we derived a national total of

Table 2 Clinical & laboratory results from hospital record
reviews in Hanoi and Ho Chi Minh City, Vietnam, January
2004 through December 2005
Case category

Hanoi

Ho Chi
Minh City

Suspected meningitis

145

1115

Purulent CSF specimens, children < 5 years

85

404

Purulent meningitis cases in which a bacterial
pathogen was identified

17

34

Purulent meningitis cases in which Hib was
identified

10

15

Child deaths due to Hib meningitis

0

1

35 Hib meningitis deaths and 441 Hib pneumonia
deaths. Using the alternative method (the “U5MR”
method), a total of 77 Hib meningitis deaths and 957
Hib pneumonia deaths were estimated at the national
level. In addition, these two methods estimated that
there are a total of 883 to 1,915 cases of Hib meningitis
and 4,414 to 9,574 cases of Hib pneumonia per year in
Vietnam among children < 5 years of age. Using the
standardized worksheet for the incidence estimation, the
estimated Hib meningitis incidence among children < 5
years of age was 9.8/100,000 (95% CI, 6.5-14.8) in Hanoi
and 22.5/100,000 (95% CI, 18.4-27.5) in Ho Chi Minh
City. Overall, the incidence rate of Hib meningitis
among children < 5 years of age in Vietnam was 18/
100,000 (95% CI, 15.1-21.6).

Discussion
This study demonstrates that Hib disease is an important disease among children < 5 years of age in Vietnam.
Since 1998, six studies of Hib disease have been conducted at major hospitals in Vietnam [9,19-23]. In addition, national Vietnamese agencies have conducted
prospective, population-based surveillance over a twoyear period from 2000 to 2002 [9]. This study focused
on acute Hib meningitis among children less than five
years of age. The overall incidence rate of Hib meningitis was 12/100,000 children < 5 years of age. Given that
this study only considered Hib meningitis, previous studies that determined the ratio of Hib pneumonia to Hib
meningitis allowed us to estimate the total incidence of
Hib disease (including Hib pneumonia would result in a
total incidence rate of 60/100,000 in children < 5 years
of age) [24,25].
This study has some limitations. In Vietnam, relatively
few clinical hospital microbiology laboratories have the
capacity for Hib culture and identification. This situation is slowly improving but Hib bacterial culture
laboratory capacity is mostly restricted to large,
national- or regional-level tertiary care hospitals located
in major cities such as Hanoi and Ho Chi Minh City. As
a result, data inputs for the Hib RAT were only
obtained from large hospitals. More recently in Vietnam
(June 2010), Hib vaccine was introduced as a component of a pentavalent vaccine into the routine immunization program. With this new vaccine introduction,
efforts are underway to conduct routine hospital-based
sentinel surveillance for Hib with improved laboratory
diagnosis using CSF/blood culture, bacterial antigen
detection, and nucleic acid testing (e.g., polymerase
chain reaction). These surveillance efforts will be critical
to understanding the future impact of Hib vaccines in
Vietnam.
The diagnosis of Hib pneumonia is difficult even
under the best of circumstances because a very high
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proportion of bacterial cultures are negative. For that
reason, it is believed that the proportion of all-cause
pneumonia attributable to Hib can be ascertained most
accurately using the Hib vaccine as a probe [26]. In Hib
vaccine probe studies, rates of pneumonia are compared
between groups of children who receive or do not
receive the Hib conjugate vaccine. The percentage
reduction in Hib disease observed between these two
groups provides indirect information on the proportion
of pneumonia due to Hib. Knowledge of the burden of
Hib pneumonia relative to Hib meningitis from previous
Hib vaccine probe studies suggests that Hib pneumonia
is five times more common compared to Hib meningitis
[24,25]. Because these studies were limited to only two
populations from the Gambia and Chile, it is arguable
that this ratio may be different in other settings. Nevertheless, because there have been few Hib vaccine probe
studies in which pneumonia was assessed in a standardized fashion, this ratio has been utilized in the Hib
RAT to derive the total number of Hib disease cases
and deaths. The range of Hib meningitis and pneumonia
deaths found in Vietnam and other Hib RAT studies
results from the application of two different estimation
methods that utilize different assumptions, sources of
data and formulae to derive the meningitis and pneumonia deaths figure [14,27].
Hib disease burden studies in developed countries are
time-consuming and very expensive [28]. In less-developed countries, such studies pose unique challenges for
existing technical capacities, logistics, and programmatic
sustainability. The primary goal behind the Hib rapid disease burden assessment is to provide an easily attainable
yet easy-to-implement estimate of the Hib burden of disease. The results of rapid disease burden assessment studies may suffer from perceptions of low credibility since
the underlying assumptions of the rapid disease burden
assessment tool are based on limited clinical, epidemiological or laboratory data. Nevertheless, rapid disease burden assessment tools have been used in a wide range of
countries to enhance basic understanding of Hib disease.
In Vietnam, the Hib RAT data analysis was also used to
derive the estimated incidence rates of Hib disease. Interestingly, the results of this analysis fall within the range
of the 95% confidence intervals found in the prospective
study of Hib and pneumococcal disease conducted in
Khanh Hoa province in Vietnam from 2005-2006 with
support from PneumoADIP [19]. In this study, the incidence of all Hib disease was found to be 22.9/100,000
(95% CI, 10.3-51.2) in children less than five years of age.
Furthermore, these results also overlap with the incidence rate of Hib meningitis found in Hanoi, Vietnam
[9]. The incidence rates for Hib disease in Vietnam are
also consistent with those found in several European
countries prior to conjugate Hib vaccine introduction
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into routine immunization programs [29]. Thus, conducting the Hib RAT assessment in Vietnam has allowed
us to confirm findings from previous population-based
incidence studies conducted in Vietnam. Furthermore,
future use of the Hib RAT to periodically estimate the
burden of Hib disease following Hib vaccine introduction
may give national agencies an additional tool with which
to assess the impact of Hib vaccination.

Conclusion
Despite potential limitations of the Hib RAT in terms of
data inputs from only a few laboratories, and making
assumptions with respect to the ratio of Hib pneumonia
to Hib meningitis, the Hib RAT appears to provide a valid
approach to approximating the incidence rate and burden
of Hib disease among children < 5 years of age. Previous
to this study, the consistency of incidence rates derived
from Hib RAT assessments and population-based studies
conducted in the same country have never been shown.
These encouraging results suggest that rapid disease burden assessment tools may be developed and validated for
other diseases. Such rapid assessment tools may be particularly valuable in resource-limited settings where laboratory-based surveillance is challenging to sustain.
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